GILD
Price
$113.59
Change
+$0.90 (+0.80%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
140.93B
16 days until earnings call
PFE
Price
$26.43
Change
-$0.94 (-3.43%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
150.27B
28 days until earnings call
Interact to see
Advertisement

GILD vs PFE

Header iconGILD vs PFE Comparison
Open Charts GILD vs PFEBanner chart's image
Gilead Sciences
Price$113.59
Change+$0.90 (+0.80%)
Volume$89.56K
Capitalization140.93B
Pfizer
Price$26.43
Change-$0.94 (-3.43%)
Volume$304.77K
Capitalization150.27B
GILD vs PFE Comparison Chart in %
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. PFE commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and PFE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (GILD: $113.58 vs. PFE: $26.43)
Brand notoriety: GILD and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 130% vs. PFE: 121%
Market capitalization -- GILD: $140.93B vs. PFE: $150.27B
GILD [@Pharmaceuticals: Major] is valued at $140.93B. PFE’s [@Pharmaceuticals: Major] market capitalization is $150.27B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $757.55B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $95.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).

  • GILD’s FA Score: 4 green, 1 red.
  • PFE’s FA Score: 2 green, 3 red.
According to our system of comparison, GILD is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 2 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • GILD’s TA Score: 2 bullish, 7 bearish.
  • PFE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PFE is a better buy in the short-term than GILD.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а +0.85% price change this week, while PFE (@Pharmaceuticals: Major) price change was +10.82% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.67%. For the same industry, the average monthly price growth was +2.59%, and the average quarterly price growth was +23.70%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+4.67% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($150B) has a higher market cap than GILD($141B). GILD has higher P/E ratio than PFE: GILD (22.54) vs PFE (13.98). GILD YTD gains are higher at: 25.570 vs. PFE (4.983). PFE has higher annual earnings (EBITDA): 20.2B vs. GILD (11B). GILD has less debt than PFE: GILD (24.9B) vs PFE (60.9B). PFE has higher revenues than GILD: PFE (63.8B) vs GILD (28.9B).
GILDPFEGILD / PFE
Capitalization141B150B94%
EBITDA11B20.2B54%
Gain YTD25.5704.983513%
P/E Ratio22.5413.98161%
Revenue28.9B63.8B45%
Total CashN/A13.2B-
Total Debt24.9B60.9B41%
FUNDAMENTALS RATINGS
GILD vs PFE: Fundamental Ratings
GILD
PFE
OUTLOOK RATING
1..100
2629
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
11
Undervalued
PROFIT vs RISK RATING
1..100
1297
SMR RATING
1..100
2962
PRICE GROWTH RATING
1..100
3022
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
12n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (11) in the Pharmaceuticals Major industry is in the same range as GILD (15) in the Biotechnology industry. This means that PFE’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for PFE (97) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than PFE’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for PFE (62) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than PFE’s over the last 12 months.

PFE's Price Growth Rating (22) in the Pharmaceuticals Major industry is in the same range as GILD (30) in the Biotechnology industry. This means that PFE’s stock grew similarly to GILD’s over the last 12 months.

PFE's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as GILD (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDPFE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
61%
Bearish Trend 4 days ago
49%
Momentum
ODDS (%)
Bearish Trend 4 days ago
45%
Bullish Trend 4 days ago
46%
MACD
ODDS (%)
Bearish Trend 4 days ago
41%
Bullish Trend 4 days ago
48%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 4 days ago
52%
Advances
ODDS (%)
Bullish Trend 8 days ago
60%
Bullish Trend 6 days ago
57%
Declines
ODDS (%)
Bearish Trend 12 days ago
47%
Bearish Trend 12 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
46%
Bearish Trend 4 days ago
53%
Aroon
ODDS (%)
Bearish Trend 4 days ago
48%
Bearish Trend 4 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FNDF43.810.08
+0.18%
Schwab Fundamental International Eq ETF
OCTM32.220.01
+0.03%
FT Vest U.S. Equity Max Buffer ETF – Oct
THTA15.11-0.02
-0.15%
SoFi Enhanced Yield ETF
NBSM25.60-0.06
-0.23%
Neuberger Berman Small-Mid Cap ETF
AUSF46.32-0.24
-0.52%
Global X Adaptive US Factor ETF

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.79%
BMY - GILD
46%
Loosely correlated
-0.68%
GSK - GILD
42%
Loosely correlated
+0.23%
NVS - GILD
40%
Loosely correlated
-0.11%
AMGN - GILD
40%
Loosely correlated
-1.27%
PFE - GILD
37%
Loosely correlated
-3.43%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
-3.43%
GSK - PFE
61%
Loosely correlated
+0.23%
NVS - PFE
60%
Loosely correlated
-0.11%
BIIB - PFE
59%
Loosely correlated
-3.65%
BMY - PFE
57%
Loosely correlated
-0.68%
ABBV - PFE
56%
Loosely correlated
-1.59%
More